Biomarker-driven treatment for muscle-invasive bladder cancer (MIBC) led to a 2-year metastasis-free survival (MFS) rate that ...

Partial and radical cystectomy offer comparable oncologic outcomes in well-selected patients with muscle-invasive bladder cancer, according to study findings presented at the 2024 annual meeting of ...

The following is a summary of “Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive ...

Patients found to have positive lymph nodes after robotic radical cystectomy for muscle-invasive bladder cancer may benefit from treatment de-escalation if they have undetectable circulating tumor DNA ...

The US Food and Drug Administration (FDA) has granted priority review to AstraZeneca's supplemental biologics licence ...

Opens in a new tab or window Bladder-preserving trimodality therapy may be a potential alternative to radical cystectomy in patients with high-grade T1 bladder cancer that has progressed despite ...

Survival according to treatment group and complete pathologic response (pT0) in patients treated with either neoadjuvant MVAC and cystectomy or cystectomy alone. Hazard ratios for subgroups ...

Early radical cystectomy can be beneficial and should be performed in patients with refractory T1 tumors or carcinoma in situ before progression to muscle invasion. In this Review I present an ...

Radical cystectomy (RC) is a morbid operation with a high rate of perioperative complications. If patients survive their cancer, long-term complications significantly impact their quality of life. Dr.

At ESMO 2024, Dr. Andrea Necchi presented the results of an interim analysis of SunRISe-4, noting a pathological complete response rate in the combination arm of 42% and pathologic objective response ...

Cambridge: AstraZeneca's supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) has been accepted and ...